Stockhead’s Sarah Hughan sits down with AROA Biosurgery (ASX:ARX) founder and CEO Brian Ward to get the short end of the long story on the company’s latest news.

The soft-tissue regeneration company released its FY24 financial results with a total revenue of NZ$69.1M, buoyed by sales of its Myriad wound-healing innovations.

It’s also looking to commercialise its Enivo device with an estimated market opportunity in excess of US$1B.

Tune in to hear AROA Biosurgery’s Brian Ward on the financial highlights, its growing portfolio, and more.